Increasing Awareness And Improved Drug Options Hold Key To Future Of European Endometriosis Therapeutics Market

The European endometriosis
therapeutics market will experience sustained growth in the coming years.
Rising awareness about the condition coupled with the anticipated launch
of improved products will be the major driving forces in market expansion.



New analysis from Frost & Sullivan (pharma.frost), European
Endometriosis Therapeutics Market, finds that this market was valued at
$365.0 million in 2006 and estimates this to reach $511.6 million in 2013.



If you are interested in a virtual brochure, which provides manufacturers,
end users and other industry participants with an overview of the latest
analysis of the European Endometriosis Therapeutics Market, send an e-mail
to Radhika Menon Theodore, Corporate Communications, at
rmtheodorefrost with your full name, company name, title, telephone
number, e-mail address, city, state and country. We will send you the
information through e-mail upon receipt of the above information.



"With a large untreated population, endometriosis remains a considerably
underdeveloped market," says Frost & Sullivan Research Analyst Vaibhav
Sarvesh. "However, patient awareness about the condition has been
increasing, setting the stage for enhanced market penetration."



The projected introduction of novel products with better side effects
together with changing raising awareness will help increase adoption
levels of endometriosis therapeutics across Europe.



"GnRH Antagonist and progestins with longer treatment periods will be the
most important treatment options that will support market expansion,"
notes Mr. Sarvesh. "Heightened awareness due to information dissemination
campaigns, paralleled by the availability of products with enhanced safety
profiles will positively impact market growth."



The current lack of efficient and non-invasive diagnostic procedures as
well as the negative side effects of existing therapeutics is restraining
the market from growing at its real potential. An aging population and
restrictive reimbursement policies are further impeding market growth.



"Laparoscopy is considered the gold standard for the diagnosis of
endometriosis, but this procedure is invasive and costly," adds Mr.
Sarvesh. "No new procedures are expected to be launched in the near
future, thereby will continue to hinder market growth."



At the same time, the side effect of current treatment options,
particularly the effect of some of the drugs on bone density, will pose a
major challenge to market expansion until new treatments are introduced.



Considering the large population of untreated patients, increasing
awareness will be the key to market growth. Promoting knowledge about the
disease coupled with the launch of drugs with fewer side effects will be
critical to sustaining market development. Although antagonists are
expected to drive the market in the future, success also awaits any
innovative therapeutic approach such as the use of progestin modulators.



European Endometriosis Therapeutics Market is part of the Pharmaceutical &
Biotechnology Growth Partnership Service, which also includes research in
the following markets: European Urinary Incontinence Therapeutics Market,
European Blockbusters coming off patent - Opportunities for Generics, and
European Osteoarthritis Therapeutics Market. All research included in
subscriptions provide detailed market opportunities and industry trends
that have been evaluated following extensive interviews with market
participants. Interviews with the press are available.



Frost & Sullivan, a global growth consulting company, has been partnering
with clients to support the development of innovative strategies for more
than 40 years. The company's industry expertise integrates growth
consulting, growth partnership services, and corporate management training
to identify and develop opportunities. Frost & Sullivan serves an
extensive clientele that includes Global 1000 companies, emerging
companies, and the investment community by providing comprehensive
industry coverage that reflects a unique global perspective and combines
ongoing analysis of markets, technologies, econometrics, and demographics.


frost